MAMonica Amendolara

Monica Amendolara

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Monica Amendolara has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The impact of PAP therapy first impression on short-term treatment adherence

    by Monica Amendolara, Valentina Di Lecce, Carla Santomasi, Vitaliano Nicola Quaranta, Andrea Portacci, Ilaria Dei Lazzaretti, Laura Anna Sara Cuccaro, Massimo Casparrini, Sebastiano Spierto, Vito Picerno, et al.

    Purpose: Positive airway pressure (PAP) treatment for obstructive sleep apnea syndrome (OSAS) is often burdened by lower adherence rates. Patients’ perception and acceptance of PAP therapy play a crucial role in achieving acceptable adherence. Method: We conducted a prospective cohort study to assess patients’ initial impressions of PAP therapy using a six-item questionnaire. The questionnaire evaluated CPAP tolerance, interface comfort, titration pressure, likelihood of CPAP use, expected health benefits, and overall attitude toward PAP therapy. Patients underwent a baseline awake PAP therapy trial (T0) followed by titration with an automatic device (APAP). After one month of titration, a fixed CPAP value was set (T1). Follow-ups occurred at 1 (T2), 3 (T3), and 6 (T4) months after the start of treatment. Adherence to PAP therapy was considered sufficient if the mean device usage was ≥ 4 h/night at T4. Results: After six months, 77% of the enrolled patients achieved high PAP treatment adherence. Questionnaire scores generally improved from T0 to T4, particularly in CPAP tolerance, likelihood of treatment adherence, expected health benefits, and overall judgment of PAP therapy. Time-to-event analysis revealed that higher baseline scores in titration pressure comfort, likelihood of CPAP adherence, and overall judgment of PAP therapy were significantly associated with higher adherence likelihood. Conclusion: Patients’ first judgement on PAP therapy could significantly influence short-term adherence. Early identification and management of patients’ complaints and discomforts could improve adherence rates and PAP perception over time.


  • Diaphragm function in patients with asthma and healthy controls: A cross-sectional study

    by Andrea Portacci, Ilaria Iorillo, Vitaliano Nicola Quaranta, Monica Amendolara, Flogerta Sana, Valeria Pezzuto, Santina Ferrulli, Silvano Dragonieri, Giovanna Elisiana Carpagnano


  • Open Access

    The Role of Galectins in Asthma Pathophysiology: A Comprehensive Review

    by Andrea Portacci, Ilaria Iorillo, Leonardo Maselli, Monica Amendolara, Vitaliano Nicola Quaranta, Silvano Dragonieri, Giovanna Elisiana Carpagnano

    Galectins are a group of β-galactoside-binding proteins with several roles in immune response, cellular adhesion, and inflammation development. Current evidence suggest that these proteins could play a crucial role in many respiratory diseases such as pulmonary fibrosis, lung cancer, and respiratory infections. From this standpoint, an increasing body of evidence have recognized galectins as potential biomarkers involved in several aspects of asthma pathophysiology. Among them, galectin-3 (Gal-3), galectin-9 (Gal-9), and galectin-10 (Gal-10) are the most extensively studied in human and animal asthma models. These galectins can affect T helper 2 (Th2) and non-Th2 inflammation, mucus production, airway responsiveness, and bronchial remodeling. Nevertheless, while higher Gal-3 and Gal-9 concentrations are associated with a stronger degree of Th-2 phlogosis, Gal-10, which forms Charcot–Leyden Crystals (CLCs), correlates with sputum eosinophilic count, interleukin-5 (IL-5) production, and immunoglobulin E (IgE) secretion. Finally, several galectins have shown potential in clinical response monitoring after inhaled corticosteroids (ICS) and biologic therapies, confirming their potential role as reliable biomarkers in patients with asthma.


  • Can Galectin-3 be a reliable predictive biomarker for post-COVID syndrome development?

    by Andrea Portacci, Monica Amendolara, Vitaliano Nicola Quaranta, Ilaria Iorillo, Enrico Buonamico, Fabrizio Diaferia, Sara Quaranta, Cristian Locorotondo, Annalisa Schirinzi, Esterina Boniello, et al.